Deregulated cellular circuits driving immunoglobulins and complement consumption associate with the severity of COVID‐19 patients

Ana Marcos‐Jiménez(Health First), Santiago Sánchez‐Alonso(Health First), Ana Alcaraz‐Serna(Hospital Universitario de La Princesa), Laura Esparcia(Hospital Universitario de La Princesa), Celia López‐Sanz(Hospital Universitario de La Princesa), Miguel Sampedro‐Núñez(Hospital Universitario de La Princesa), Tamara Mateu‐Albero(Hospital Universitario de La Princesa), Ildefonso Sánchez‐Cerrillo(Hospital Universitario de La Princesa), Pedro Martínez‐Fleta(Hospital Universitario de La Princesa), Ligia Gabrie(Hospital Universitario de La Princesa), Luciana del Campo Guerola(Hospital Universitario de La Princesa), José Miguel Rodrı́guez-Frade(Centro Nacional de Biotecnología), José M. Casasnovas(Centro Nacional de Biotecnología), Hugh T. Reyburn(Centro Nacional de Biotecnología), Mar Valés‐Gómez(Centro Nacional de Biotecnología), Margarita López‐Trascasa(Universidad Autónoma de Madrid), Enrique Martín‐Gayo(Hospital Universitario de La Princesa), Marı́a J. Calzada(Hospital Universitario de La Princesa), Santos Castañeda(Hospital Universitario de La Princesa), Hortensia de la Fuente(Hospital Universitario de La Princesa), Isidoro González‐Álvaro(Hospital Universitario de La Princesa), Francisco Sánchez‐Madrid(Hospital Universitario de La Princesa), Cecilia Muñoz‐Calleja(Hospital Universitario de La Princesa), Arántzazu Alfranca(Hospital Universitario de La Princesa)
European Journal of Immunology
November 30, 2020
Cited by 52Open Access
Full Text

Abstract

Abstract SARS‐CoV‐2 infection causes an abrupt response by the host immune system, which is largely responsible for the outcome of COVID‐19. We investigated whether the specific immune responses in the peripheral blood of 276 patients were associated with the severity and progression of COVID‐19. At admission, dramatic lymphopenia of T, B, and NK cells is associated with severity. Conversely, the proportion of B cells, plasmablasts, circulating follicular helper T cells (cTfh) and CD56 – CD16 + NK‐cells increased. Regarding humoral immunity, levels of IgM, IgA, and IgG were unaffected, but when degrees of severity were considered, IgG was lower in severe patients. Compared to healthy donors, complement C3 and C4 protein levels were higher in mild and moderate, but not in severe patients, while the activation peptide of C5 (C5a) increased from the admission in every patient, regardless of their severity. Moreover, total IgG, the IgG1 and IgG3 isotypes, and C4 decreased from day 0 to day 10 in patients who were hospitalized for more than two weeks, but not in patients who were discharged earlier. Our study provides important clues to understand the immune response observed in COVID‐19 patients, associating severity with an imbalanced humoral response, and identifying new targets for therapeutic intervention.


Related Papers

No related papers found

Powered by citation graph analysis